{"transactions":[{"id":4626229,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-24T20:40:34.000Z","date":"2026-09-22","kind":"purchase","planned":false,"acquired":true,"shares":5102,"price":1.97,"value":10050.94,"ownership":{"direct":true},"balance_after":5102,"source":{"system":"sec-edgar","filing":"0001552781-26-000501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000155278126000501/ownership.xml","form_type":"4"}},{"id":733219,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:40:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company."}],"balance_after":200000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000929638-26-002260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963826002260/form4.xml","form_type":"4"}},{"id":733218,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:40:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963826002260/form4.xml","form_type":"4"}},{"id":801634,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:31:53.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the \"RSU Vesting Date\"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001730229-26-000001","document":"form4-04232026_080449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022926000001/form4-04232026_080449.xml","form_type":"4"}},{"id":801633,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:31:53.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.01,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001730229-26-000001","document":"form4-04232026_080449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022926000001/form4-04232026_080449.xml","form_type":"4"}},{"id":801632,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:31:53.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32335,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001730229-26-000001","document":"form4-04232026_080449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022926000001/form4-04232026_080449.xml","form_type":"4"}},{"id":801631,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:31:53.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":66660},"source":{"system":"sec-edgar","filing":"0001730229-26-000001","document":"form4-04232026_080449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022926000001/form4-04232026_080449.xml","form_type":"4"}},{"id":1004567,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T22:59:43.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options are fully vested."}],"balance_after":32335,"derivative":{"exercise_price":8.99,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001730229-25-000004","document":"form4-11072025_101140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022925000004/form4-11072025_101140.xml","form_type":"4"}},{"id":1004566,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T22:59:43.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.87,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001730229-25-000004","document":"form4-11072025_101140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022925000004/form4-11072025_101140.xml","form_type":"4"}},{"id":1004565,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T22:59:43.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":66660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":66660,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":66660},"source":{"system":"sec-edgar","filing":"0001730229-25-000004","document":"form4-11072025_101140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022925000004/form4-11072025_101140.xml","form_type":"4"}},{"id":1004564,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T22:59:43.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.81,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":66660},"source":{"system":"sec-edgar","filing":"0001730229-25-000004","document":"form4-11072025_101140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000173022925000004/form4-11072025_101140.xml","form_type":"4"}},{"id":1089044,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-10T20:06:13.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of Dr. Grossman's date of appointment to the Board, which was July 8, 2025."}],"balance_after":45000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000929638-25-002556","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963825002556/form4.xml","form_type":"4"}},{"id":1122338,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-06-04T21:54:17.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the \"RSU Vesting Date\"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-015631","document":"form4-06042025_090613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000141588925015631/form4-06042025_090613.xml","form_type":"4"}},{"id":1122337,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-06-04T21:54:17.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":22500,"derivative":{"exercise_price":7.01,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001415889-25-015631","document":"form4-06042025_090613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000141588925015631/form4-06042025_090613.xml","form_type":"4"}},{"id":1499905,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2024-05-28T22:44:36.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":32335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":32335,"derivative":{"exercise_price":13.87,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":32335},"source":{"system":"sec-edgar","filing":"0001415889-24-014729","document":"form4-05282024_100533.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000141588924014729/form4-05282024_100533.xml","form_type":"4"}},{"id":1674920,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2024-01-19T22:22:55.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":66660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":66660,"derivative":{"exercise_price":13.81,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":66660},"source":{"system":"sec-edgar","filing":"0001209191-24-001950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000120919124001950/doc4.xml","form_type":"4"}},{"id":2661257,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-21T20:48:59.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":3891,"price":23.68,"value":92138.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":20723,"source":{"system":"sec-edgar","filing":"0001209191-21-042074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121042074/doc4.xml","form_type":"4"}},{"id":2661256,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-21T20:48:59.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":127,"price":24.77,"value":3145.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":24614,"source":{"system":"sec-edgar","filing":"0001209191-21-042074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121042074/doc4.xml","form_type":"4"}},{"id":2661255,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-21T20:48:59.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":3047,"price":24.13,"value":73524.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,071 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan"}],"balance_after":24741,"source":{"system":"sec-edgar","filing":"0001209191-21-042074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121042074/doc4.xml","form_type":"4"}},{"id":2739680,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-26T20:14:36.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":4133,"price":31.37,"value":129652.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold in a private transaction to Dr. Yasunori Kaneko, a director of Arcus Biosciences, Inc.  The shares, representing approximately 1.6% of the total shares either owned or that may be acquired by Dr. Grossman upon exercise of options that are vested and exercisable, were sold by Dr. Grossman as part of his tax plan."}],"balance_after":6717,"source":{"system":"sec-edgar","filing":"0001179110-21-004603","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000117911021004603/edgar.xml","form_type":"4"}},{"id":2779437,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-18T20:37:27.000Z","date":"2021-03-16","kind":"sale","acquired":false,"shares":2127,"price":35.0299,"value":74508.5973,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.98 to $35.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":10850,"source":{"system":"sec-edgar","filing":"0001209191-21-021772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121021772/doc4.xml","form_type":"4"}},{"id":2902497,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-20T21:11:44.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":112500,"derivative":{"exercise_price":36.73,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001209191-21-004265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121004265/doc4.xml","form_type":"4"}},{"id":2902496,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-20T21:11:44.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":25477,"source":{"system":"sec-edgar","filing":"0001209191-21-004265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121004265/doc4.xml","form_type":"4"}},{"id":2938064,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-18T21:51:58.000Z","date":"2020-12-16","kind":"sale","acquired":false,"shares":2117,"price":31.35,"value":66367.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 992 shares purchased on 5/29/2020 and 1,002 shares purchased on 11/30/2020 through the Company's Employee Stock Purchase Plan."}],"balance_after":6727,"source":{"system":"sec-edgar","filing":"0001209191-20-064444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120064444/doc4.xml","form_type":"4"}},{"id":3013482,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-05T21:02:24.000Z","date":"2020-10-02","kind":"grant","acquired":true,"shares":100000,"price":17,"value":1700000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable in 48 equal monthly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company."}],"balance_after":100000,"derivative":{"exercise_price":17,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-053710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120053710/doc4.xml","form_type":"4"}},{"id":3013481,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-10-05T21:02:24.000Z","date":"2020-10-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in quarterly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company."}],"balance_after":100600,"source":{"system":"sec-edgar","filing":"0001209191-20-053710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120053710/doc4.xml","form_type":"4"}},{"id":3069787,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-08-04T22:13:31.000Z","date":"2020-07-31","kind":"purchase","acquired":true,"shares":100,"price":19.6756,"value":1967.56,"ownership":{"direct":true},"balance_after":600,"source":{"system":"sec-edgar","filing":"0001209191-20-044798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120044798/doc4.xml","form_type":"4"}},{"id":3069786,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-08-04T22:13:31.000Z","date":"2020-07-31","kind":"purchase","acquired":true,"shares":100,"price":19.77,"value":1977.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-20-044798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120044798/doc4.xml","form_type":"4"}},{"id":3118847,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-06-08T20:26:20.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company."}],"balance_after":55400,"source":{"system":"sec-edgar","filing":"0001209191-20-034978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120034978/doc4.xml","form_type":"4"}},{"id":3305423,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-22T15:44:36.000Z","date":"2020-01-17","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable in 48 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company."}],"balance_after":140000,"derivative":{"exercise_price":10.23,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-20-004398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120004398/doc4.xml","form_type":"4"}},{"id":3393739,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-15T22:15:35.000Z","date":"2019-10-14","kind":"purchase","acquired":true,"shares":300,"price":8,"value":2400.0,"ownership":{"direct":true},"balance_after":400,"source":{"system":"sec-edgar","filing":"0001209191-19-053207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919119053207/doc4.xml","form_type":"4"}},{"id":3393738,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-15T22:15:35.000Z","date":"2019-10-10","kind":"purchase","acquired":true,"shares":100,"price":8,"value":800.0,"ownership":{"direct":true},"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-19-053207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919119053207/doc4.xml","form_type":"4"}},{"id":3544485,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-05-01T20:16:03.000Z","date":"2019-04-29","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable in 48 equal monthly installments after April 29, 2019, subject to the Reporting Person's continued service to the Company."}],"balance_after":400000,"derivative":{"exercise_price":10.49,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-19-026755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919119026755/doc4.xml","form_type":"4"}},{"id":3670101,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-07T16:02:03.000Z","date":"2019-02-05","kind":"tax_withholding","acquired":false,"shares":3126,"price":3.48,"value":10878.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 5, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to the reporting person on February 5, 2018 for 30,000 shares, which vest in four equal annual installments on each anniversary of February 5, 2018."}],"balance_after":26874,"source":{"system":"sec-edgar","filing":"0001358403-19-000026","document":"wf-form4_154957330959098.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840319000026/wf-form4_154957330959098.xml","form_type":"4"}},{"id":3673743,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-05T16:09:01.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":82500,"derivative":{"exercise_price":3.35,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001358403-19-000019","document":"wf-form4_154940092828630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840319000019/wf-form4_154940092828630.xml","form_type":"4"}},{"id":4071933,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-02-07T18:06:35.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option vest and become exercisable on February 5, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":175000,"derivative":{"exercise_price":5.61,"expiration_date":"2028-02-04","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-18-008213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000120919118008213/doc4.xml","form_type":"4"}},{"id":4071932,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-07T18:06:35.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments on each anniversary of February 5, 2018."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-18-008213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000120919118008213/doc4.xml","form_type":"4"}}]}